<DOC>
	<DOCNO>NCT02553265</DOCNO>
	<brief_summary>The overall study objective determine whether carbidopa ( LodosynÂ® ) safe well tolerate ass whether inhibit catecholamine-induced paroxysmal hypertension normalize reduce exaggerated blood pressure variability patient familial dysautonomia ( FD , also call hereditary sensory autonomic neuropathy type III Riley-Day syndrome ) . Funding Source- FDA OOPD .</brief_summary>
	<brief_title>Carbidopa Treatment Excessive Blood Pressure Variability</brief_title>
	<detailed_description>The investigator propose perform double-blind randomize trial cross design compare high dose ( 600 mg/day ) low dose ( 300 mg per day ) carbidopa blockade placebo . Patients randomly assign high-dose/low-dose/placebo sequence , lowdose/placebo/high-dose sequence placebo/high-dose/low-dose sequence . Participants remain treatment period 28-days . Aim 1 : To evaluate safety tolerability carbidopa FD patient particular emphasis orthostatic fall blood pressure . Aim 2 : As proof concept , examine hemodynamic effect carbidopa determine effect norepinephrine production , BP variability paroxysmal hypertension . Aim 3 : In dose finding study , compare effect low ( 300 mg/day ) high ( 600 mg/day ) dose carbidopa blockade vs. placebo BP variability paroxysmal hypertension .</detailed_description>
	<mesh_term>Primary Dysautonomias</mesh_term>
	<mesh_term>Autonomic Nervous System Diseases</mesh_term>
	<mesh_term>Dysautonomia , Familial</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<criteria>Male female patient familial dysautonomia ( FD ) age 12 old Unstable blood pressure , define : Systolic BP standard deviation &gt; 15 mmHg Or coefficient variation &gt; 15 % Or document episodic hypertensive peak ( &gt; 140mmHg ) Confirmed diagnosis FD ( genetic testing ) Providing write informed consent ( ascent ) participate trial Ability comply requirement study procedure . Patients take monoamine oxidase ( MAO ) inhibitor Patients take : metoclopramide , domperidone , risperidone dopamine blocker Patients take tricyclic antidepressant Patients take neuroleptic drug ( haloperidol chlorpromazine ) Patients known hypersensitivity component drug . Patients atrial fibrillation , angina significant ECG abnormality Patients significant pulmonary , cardiac , liver , renal ( creatinine &gt; 2.0 mg/ml ) Patients significant abnormality clinical examination may , investigator 's opinion might jeopardize healthy participate trial . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Familial dysautonomia ( HSAN III )</keyword>
	<keyword>Norepinephrine</keyword>
	<keyword>Sympathetic nervous system</keyword>
	<keyword>Autonomic nervous system</keyword>
	<keyword>Blood pressure variability</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Carbidopa/Lodosyn</keyword>
	<keyword>Afferent baroreflex failure</keyword>
	<keyword>Clinical trial</keyword>
</DOC>